Overview

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The objective of the Treatment Phase of the study is to evaluate the safety and efficacy of 4 weeks of once daily oral administration of BLI5100 low dose, BLI5100 high dose, or placebo in patients with NERD. The objective of the Extension Phase of the study is to evaluate the safety of 20 weeks of once daily oral administration of BLI5100 low dose and BLI5100 high dose in patients with NERD.
Phase:
Phase 3
Details
Lead Sponsor:
Braintree Laboratories